NEWS
Fibronostics Raises
$8 Million in Series A Financing.
The American Medical Association (AMA) and The Centers for Medicare & Medicaid Services (CMS) awarded LIVERFASt™ a CPT Code with the highest reimbursement fee in its category!
| Name |
|---|
Fibronostics on its way to be a Healthcare Technology Powerhouse – Raises $8 Million Series A funding. Aug 24, 2020 
Fibronostic’s Chief Scientific Officer,Dr Mona Munteanu, discussed relevance of Non-Invasive Testing for HCC Surveillance in global Webinar series. Aug 21, 2020 
Sought-after Hepatology and Gastroenterology expert, Prof. Stephen A. Harrison MD joins Fibronostics’ Advisory Board. Aug 05, 2020 |
LIVERFASt screening and diagnostics capabilities combines with Health Catalyst National Registry power up a COVID19 study. Jun 08, 2020 
Know the advantages of non-invasive liver diagnostics over standard biopsy as explained by our CEO, Roni Amiel. Aug 21, 2020 
Celebrating a major milestone! Fibronostics granted CPT code for LIVERFASt, our non-invasive liver diagnostics tool. Aug 05, 2020 |
When things go tough due to flight restrictions, we conduct our CMEs through video conferences by our Chief Medical Officer, Dr Ronald Quiambao. Jun 08, 2020 
Fibronostics presented a Scientific poster “Assessment of fatty liver disease using a biomarker-based non-invasive algorithm LIVERFASt™ test in South-East Asia”.at the NASH-TAG 2020, UTAH for. Aug 21, 2020 |
| Name |
|---|
AC Health announces Investment in Fibronostics by launching LIVERFASt and HealthFACTR in its FamilyDOC Clinics. Jul 06, 2019 
Fibronostics presented our corporate strategy to current & potential investors in TKS 1 Investor Day in Singapore. Feb 27, 2019 
Fibronostics mingles with industry leaders during inspiring few days at the American Association for the Study of Liver Diseases (AASLD) #LiverMtg19. Nov 07, 2019 |
Fibronostics is proud to partner with the CXA Group offering health and wellness screenings with HealthFACTR. Dec 13, 2019 |
